Systematic external evaluation of reported population pharmacokinetic models of vancomycin in Chinese children and adolescents

Abstract

What is known and objectives: Various population pharmacokinetic (PopPK) models for vancomycin in children and adolescents have been constructed to optimize the therapeutic regimen of vancomycin. However, little is known about their predictive performance when extrapolated to different clinical centres. Therefore, the aim of this study was to externally validate the predictability of vancomycin PopPK model when extrapolated to different clinical centres and verify its applicability in an independent data set. Methods:The published models were screened from the literature and evaluated using an external data set of a total of 451 blood concentrations of vancomycin measured in 220 Chinese paediatric patients. Prediction-and simulation-based diagnostics and Bayesian forecasting were performed to evaluate the predictive performance of the models.Results: Ten published PopPK models were assessed. Prediction-based diagnostics showed that none of the investigated models met all the standards (median prediction error (MDPE) ≤ ±20%, median absolute prediction error (MAPE) ≤30%, PE% within ±20% (F 20 ) ≥35% and PE% within ±30% (F 30 ) ≥50%), indicating unsatisfactory predictability. In simulation-based diagnostics, both the visual predictive checks (VPC) and the normalized prediction distribution error (NPDE) indicated misspecification in all models. Bayesian forecasting results showed that the accuracy and precision of individual predictions could be significantly improved with one or two prior observations, but frequent monitoring might not be necessary in the clinic, since Bayesian forecasting identified that greater number of samples did not significantly improve the predictability. Model 3 established by Moffett et al showed better predictability than other models. What is new and conclusion:The 10 published models performed unsatisfactorily in prediction-and simulation-based diagnostics; none of the published models was | 821 LV et aL. How to cite this article: Lv C, Lu J, Jing L, et al. Systematic external evaluation of reported population pharmacokinetic models of vancomycin in Chinese children and adolescents. J

Clinical application of vancomycin population pharmacokinetics model in patients with hematological diseases and neutropenia

“…However, there are only a few model studies on adult neutropenic patients (Joaguim et al, 2018). Jarkowski had developed a two-compartment model of vancomycin in hematologic patients in 2012 (Jarkowski et al, 2012), while other reports focus on children (Lv et al, 2021).…”

Machine learning advances the integration of covariates in population pharmacokinetic models: Valproic acid as an example

“…Generally, the predictability of different popPK models when extrapolated to other clinical centers might remain to be compared ( Lv et al, 2021 ). An external validation study based on published VPA models by Zang et al (2022b) suggested that the absence of children, Asian ethnicity, one-compartment models, and inclusion of the covariates body weight (BW) and VPA dosage, were the most important factors contributing to good performance in their Chinese dataset.…”

Innovative Pharmacometric Approaches to Inform Drug Development and Clinical Use

“…Generally, the predictability of different popPK models when extrapolated to other clinical centers might remain to be compared (Lv et al, 2021). An external validation study based on published VPA models by Zang et al (2022b) suggested that the absence of children, Asian ethnicity, onecompartment models, and inclusion of the covariates body weight (BW) and VPA dosage, were the most important factors contributing to good performance in their Chinese dataset.…”